» Articles » PMID: 36035901

Novel Approaches for Left Atrial Pressure Relief: Device-based Monitoring and Management in Heart Failure

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

The importance of the left atrium (LA) has been emphasized in recent years as the features of heart failure (HF), especially with regard to variability in patient and pathology phenotypes, continue to be uncovered. Of note, among the population with HF with preserved ejection fraction (HFpEF), pressure or size of the LA have become a target for advanced monitoring and a therapeutic approach. In the case of diastolic dysfunction or pulmonary hypertension, which are often observed in patients with HFpEF, a conventional approach with clinical symptoms and physical signs of decompensation turned out to have a poor correlation with LA pressure. Therefore, to optimize HF treatment for these populations, several devices that are applied directly to the LA have been developed. First, two LA pressure (LAP) sensors (Heart POD and V-LAP Device) were developed and may enable patient self-management remotely with LAP-guided and physician-directed style. Second, there are device-based approaches that aim to decompress the LA directly. These include: (1) interatrial shunt devices; (2) left ventricular assist devices with LA cannulation; and (3) the left atrial assist device. While these novel device-based therapies are not yet commercially available, there is expected to be a rise in the proposition and adoption of a wider range of choices for monitoring or treating LA using device-based options, based on LA dimensional reduction and optimization of the clinically significant pressure relief. Further development and evaluation are necessary to establish a more favorable management strategy for HF.

Citing Articles

Prediction of the ideal length of insertion to monitor left atrial pressures in pediatric open-heart surgery: a retrospective cohort study.

Zhang Y, Chen X, Wu Z, Li H, Dai R, Zhang S BMC Cardiovasc Disord. 2025; 25(1):178.

PMID: 40082803 PMC: 11905710. DOI: 10.1186/s12872-025-04616-9.


Chronic Heart Failure Management: Monitoring Patients and Intercepting Exacerbations.

Piccirillo G, Moscucci F, Sciomer S, Magri D Rev Cardiovasc Med. 2024; 24(7):208.

PMID: 39077011 PMC: 11266474. DOI: 10.31083/j.rcm2407208.


Early-stage Development of the CoRISMA Mechanical Circulatory Support (CMCS) System for Heart Failure Therapy.

Monreal G, Koenig S, Kelley J, Illg J, Tamez D, Kelley M Cardiovasc Eng Technol. 2024; 15(6):667-678.

PMID: 39037566 DOI: 10.1007/s13239-024-00743-0.

References
1.
Topilsky Y, Pereira N, Shah D, Boilson B, Schirger J, Kushwaha S . Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail. 2011; 4(3):266-75. DOI: 10.1161/CIRCHEARTFAILURE.110.959288. View

2.
Reddy Y, Obokata M, Verbrugge F, Lin G, Borlaug B . Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. J Am Coll Cardiol. 2020; 76(9):1051-1064. PMC: 7455760. DOI: 10.1016/j.jacc.2020.07.009. View

3.
Wynne E, Bergin J, Ailawadi G, Kern J, Kennedy J . Use of a left ventricular assist device in hypertrophic cardiomyopathy. J Card Surg. 2011; 26(6):663-5. DOI: 10.1111/j.1540-8191.2011.01331.x. View

4.
Givertz M, Stevenson L, Costanzo M, Bourge R, Bauman J, Ginn G . Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2017; 70(15):1875-1886. DOI: 10.1016/j.jacc.2017.08.010. View

5.
Fukamachi K, Horvath D, Karimov J, Kado Y, Miyamoto T, Kuban B . Left atrial assist device to treat patients with heart failure with preserved ejection fraction: Initial in vitro study. J Thorac Cardiovasc Surg. 2020; 162(1):120-126. DOI: 10.1016/j.jtcvs.2019.12.110. View